List of Excipients in Branded Drug COMETRIQ

COMETRIQ Excipient Strategy, Patent Exposure, and Commercial Opportunities

Last updated: September 25, 2026

COMETRIQ is an oral cabozantinib capsule developed by Exelixis for progressive or metastatic medullary thyroid cancer. Its commercial formulation uses conventional pharmaceutical excipients rather than a proprietary delivery platform. The main excipient opportunities are therefore in generic-equivalent capsules, alternative oral dosage forms, administration improvements, and manufacturing cost reduction. The principal commercial constraint is that cabozantinib is a narrow-therapeutic-index oncology drug with substantial regulatory, bioequivalence, patent, and handling requirements.

What is COMETRIQ and how is it formulated?

COMETRIQ contains cabozantinib, a small-molecule tyrosine kinase inhibitor. The U.S. product is supplied as hard gelatin capsules in 20 mg and 80 mg strengths. The labeled regimen for medullary thyroid cancer is 140 mg once daily, requiring one 80 mg capsule and three 20 mg capsules per dose.[1]

The product’s excipient system is conventional for an immediate-release hard capsule.

Component	COMETRIQ formulation role
Microcrystalline cellulose	Diluent and capsule-fill carrier
Croscarmellose sodium	Superdisintegrant
Sodium starch glycolate	Superdisintegrant and wetting aid
Colloidal silicon dioxide	Glidant and flow-control agent
Stearic acid	Lubricant
Gelatin	Capsule shell
Titanium dioxide and permitted colorants	Capsule-shell opacity and identification

The precise inactive-ingredient presentation should be verified against the applicable FDA prescribing information and inactive-ingredient records before development or filing. FDA labeling identifies the product as a capsule formulation containing standard solid-dose excipients.[1]

What does the excipient system indicate about product design?

The formulation indicates a conventional powder-filled capsule rather than a lipid-based, amorphous-solid-dispersion, osmotic, depot, or modified-release platform. The likely design objectives are:

• Adequate flow into capsule shells
• Rapid disintegration
• Uniform low-dose and high-dose fills
• Acceptable chemical stability
• Reproducible dissolution
• Simple scale-up using common manufacturing equipment

This creates a relatively accessible formulation profile for generic development. The principal technical challenge is not excipient novelty. It is reproducing cabozantinib exposure within the applicable bioequivalence limits while controlling content uniformity, dissolution, degradation, and occupational exposure.

What excipient strategy is most relevant for a COMETRIQ generic?

The strongest strategy is a conservative, Q1/Q2-style formulation using the same or functionally equivalent excipients. A generic applicant would normally seek to minimize formulation differences because cabozantinib has a narrow therapeutic window and the reference product has established clinical exposure.

Recommended formulation architecture

A development program would generally prioritize:

1. Microcrystalline cellulose as the principal filler.
2. Croscarmellose sodium and sodium starch glycolate as disintegrant options.
3. Colloidal silicon dioxide for powder flow.
4. Stearic acid or another accepted lubricant at a controlled concentration.
5. Hard gelatin or suitable hypromellose capsules, subject to bioequivalence and stability data.

The formulation should avoid unnecessary changes to particle size, capsule fill weight, lubricant level, and disintegration mechanism. These variables can affect dissolution and absorption even when the active ingredient and nominal dose remain unchanged.

What are the main formulation risks?

Risk	Commercial consequence	Mitigation
Poor powder flow	Weight variability and manufacturing interruptions	Optimize particle-size distribution and glidant level
Over-lubrication	Slower wetting and dissolution	Limit blending time and lubricant concentration
Inadequate content uniformity	Batch rejection and regulatory concern	Use controlled premixing and validated sampling
Capsule-shell interaction	Stability or dissolution changes	Evaluate gelatin and hypromellose options
Cabozantinib degradation	Shelf-life reduction	Use moisture, oxygen, light, and packaging controls
Exposure variability	Bioequivalence failure or clinical concern	Conduct comparative dissolution and PK studies
Powder toxicity	Worker-safety and containment costs	Use closed handling and validated cleaning procedures

The dosage burden is commercially relevant. A 140 mg daily dose requires multiple capsules, increasing the importance of capsule identification, adherence, packaging, and dispensing accuracy.

What formulation patents protect COMETRIQ?

COMETRIQ protection is primarily associated with cabozantinib composition, pharmaceutical composition, therapeutic-use, and product-related intellectual property rather than with an unusual excipient combination. The use of standard excipients does not by itself establish freedom to operate.

A generic developer must separate four questions:

• Whether the cabozantinib active ingredient can be lawfully manufactured.
• Whether the proposed formulation reads on a still-enforceable composition or formulation claim.
• Whether the proposed indication is covered by a method-of-use patent.
• Whether the product can be marketed after FDA exclusivity and listed patent barriers expire.

The existence of a conventional excipient system can reduce formulation-design risk, but it does not eliminate patent risk. A formulation that uses different excipients may still infringe a broad pharmaceutical-composition claim. Conversely, a formulation that closely copies the reference product may increase the risk of reading on a claim directed to the composition or dosage form.

How strong is the COMETRIQ patent estate?

The estate is stronger when evaluated as a complete cabozantinib portfolio than when evaluated only by excipient claims. The main barriers are likely to arise from:

• Cabozantinib compound protection
• Pharmaceutical-composition claims
• Medullary thyroid cancer method-of-use claims
• Dosage and administration claims
• Related cabozantinib product patents associated with other formulations or indications

The commercial value of each patent depends on claim scope, terminal disclaimers, expiration dates, prosecution history, Orange Book listing status, and whether the claim is directed to COMETRIQ capsules or another cabozantinib product.

When did COMETRIQ lose regulatory exclusivity?

The FDA approved COMETRIQ on November 29, 2012, for progressive metastatic medullary thyroid cancer.[2] Because the indication received orphan-drug designation, the statutory orphan exclusivity period was seven years, extending to November 29, 2019, subject to the scope of the protected indication.[2][3]

Milestone	Date
FDA approval	November 29, 2012
Orphan-drug exclusivity period	Seven years
Expected end of original orphan exclusivity	November 29, 2019
FDA pathway for a generic	ANDA, subject to applicable patent and exclusivity barriers

Orphan exclusivity is separate from patent protection. Its expiration did not automatically authorize generic entry if listed patents remained enforceable.

What is the Orange Book status of COMETRIQ?

COMETRIQ is an FDA-approved small-molecule prescription product and is evaluated under the abbreviated new drug application framework for generic competition. It is not a biologic and therefore does not generate biosimilar competition under the Public Health Service Act.

The Orange Book is relevant for:

• Listed patents covering the drug product or approved methods of use
• Patent expiration dates
• Paragraph IV certification strategy
• Potential 30-month litigation stays
• Generic approval timing

A generic applicant may submit a Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or will not be infringed. If the patent holder brings suit within the statutory period, FDA approval can be delayed by the applicable 30-month stay, subject to court decisions and statutory exceptions.[4]

Are biosimilars a risk to COMETRIQ?

No. Cabozantinib is a small molecule, so the relevant competitive threat is a conventional generic capsule, not a biosimilar. The main regulatory routes are:

• ANDA approval for a therapeutically equivalent generic
• 505(b)(2) application for a materially different formulation or delivery system
• New drug application for a new indication, combination, or clinically differentiated dosage form

Which commercial opportunities exist for COMETRIQ excipients?

The largest opportunity is not a new excipient itself. It is supplying excipients, formulation services, or manufacturing technology that improves the economics and robustness of cabozantinib capsule production.

1. Generic capsule development

A generic manufacturer could commercialize a capsule using functionally equivalent excipients with:

• Lower raw-material cost
• Improved flowability
• Reduced segregation
• Better dissolution reproducibility
• Reduced dependence on a single supplier
• More efficient capsule-filling rates

This opportunity is strongest after relevant patent barriers expire or are successfully challenged.

2. Capsule-shell differentiation

Hypromellose capsules could provide an alternative to gelatin for manufacturers seeking:

• Vegetarian or non-animal-derived materials
• Lower moisture content
• Different oxygen and moisture performance
• Improved compatibility with selected fill materials

The change would require comparative dissolution, stability, and bioequivalence support. It would not automatically create market exclusivity.

3. Alternative oral dosage forms

Potential 505(b)(2) opportunities include:

• Lower-strength capsules for titration
• Sprinkle capsules for patients with swallowing difficulty
• Oral suspensions
• Orally disintegrating formulations
• Pediatric or geriatric dosage forms
• Reduced-dose products for toxicity management

These opportunities face substantial development barriers. Cabozantinib dosing is adjusted for adverse reactions, but any alternative dosage form must preserve predictable exposure and support safe dose manipulation. A liquid formulation also creates challenges involving solubility, physical stability, adsorption, taste, microbial control, and occupational handling.

4. Excipient and process suppliers

Commercial opportunities exist for suppliers of:

• Direct-compression or capsule-fill grades of microcrystalline cellulose
• High-efficiency superdisintegrants
• Low-moisture capsule shells
• High-purity colloidal silicon dioxide
• Pharmaceutical lubricants with consistent surface area
• Barrier packaging
• Containment and cleaning systems for potent oncology compounds

The strongest value proposition is process performance rather than ingredient novelty. Suppliers that can document lot-to-lot consistency, extractables and leachables performance, and supply continuity have a greater chance of entering a regulated oncology product.

How does COMETRIQ compare with CABOMETYX?

COMETRIQ and CABOMETYX both contain cabozantinib, but they are different marketed products with different dosage forms, strengths, approved uses, and product-specific regulatory histories.

Attribute	COMETRIQ	CABOMETYX
Active ingredient	Cabozantinib	Cabozantinib
Dosage form	Capsules	Tablets
Initial major indication	Progressive metastatic medullary thyroid cancer	Renal cell carcinoma and other approved indications
Typical product design	Immediate-release capsule fill	Immediate-release tablet
Substitution	Not automatically interchangeable with COMETRIQ	Not automatically interchangeable with COMETRIQ
Competitive route	Generic capsule	Separate cabozantinib tablet market

The existence of CABOMETYX does not make a CABOMETYX tablet automatically substitutable for COMETRIQ capsules. Product-specific labeling, dosing, bioequivalence, and patent positions must be evaluated separately.[1][5]

What patent litigation and generic launch risks affect COMETRIQ?

The principal launch scenarios are:

Scenario	Timing effect	Commercial result
No viable Paragraph IV challenge	Delayed until relevant patent barriers expire	Later generic entry
Successful Paragraph IV challenge	Potential entry before listed patent expiry	First-filer advantage may arise
Patent settlement	Entry date governed by agreement terms	Controlled competitive entry
Non-infringement or invalidity litigation loss	Delayed launch or redesign	Higher legal and development cost
Formulation redesign	May avoid a claim but require new testing	Possible 505(b)(2) or ANDA complications
Authorized generic or license	Earlier controlled competition	Lower price erosion than multiple generics

Revenue exposure depends on the size of the medullary thyroid cancer market, duration of treatment, dose reductions, and the number of generic entrants. Cabozantinib products have also generated revenue across multiple indications, but COMETRIQ capsule revenue should not be conflated with CABOMETYX tablet revenue.

What manufacturing and IP barriers remain?

The main manufacturing barriers are containment, analytical control, and scale-up. Cabozantinib is a potent oncology active ingredient, so facilities may require dedicated controls for dispensing, dust management, cleaning validation, worker protection, and cross-contamination prevention.

The main IP barriers are:

• Broad compound claims
• Pharmaceutical-composition claims
• Method-of-use claims
• Dose-regimen claims
• Patents directed to related cabozantinib products
• Patent-term adjustments and extensions
• Patent settlements affecting launch timing

Excipient substitution is most useful as a design-around tool when a claim requires a particular formulation element. It is not a general solution to compound or method-of-use patents.

Key Takeaways

• COMETRIQ is a cabozantinib immediate-release hard gelatin capsule in 20 mg and 80 mg strengths.
• Its excipient system is conventional and centers on microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate, colloidal silicon dioxide, stearic acid, and capsule-shell materials.
• The best generic strategy is a conservative formulation with equivalent disintegration, dissolution, stability, and exposure.
• Orphan-drug exclusivity began with the November 29, 2012 approval and generally expired on November 29, 2019.
• Generic competition is governed by ANDA, Orange Book, Paragraph IV, patent litigation, and settlement considerations.
• Cabozantinib is a small molecule, so biosimilars are not relevant.
• Commercial opportunities exist in generic capsules, alternative capsule shells, dosage-form reformulation, excipient supply, containment, and manufacturing services.
• COMETRIQ capsules and CABOMETYX tablets are separate products and should not be treated as automatically interchangeable.
• The most material barriers are compound, use, formulation, regulatory, and manufacturing barriers rather than excipient novelty.

FAQs

Can a generic COMETRIQ use different excipients?

Yes. An ANDA applicant may use different inactive ingredients if the formulation satisfies FDA requirements, including safety, pharmaceutical equivalence, bioequivalence, quality, and labeling standards.

Is a liquid cabozantinib formulation commercially attractive?

It could address swallowing and dose-flexibility needs, but solubility, stability, palatability, containment, and 505(b)(2) requirements make it substantially more complex than a capsule generic.

Are COMETRIQ capsules interchangeable with CABOMETYX tablets?

No. They have different dosage forms, strengths, approved product histories, and labeling. Automatic substitution should not be assumed.

Which excipient is most important for generic COMETRIQ dissolution?

Disintegrant selection and lubricant control are likely to have the greatest practical influence, together with API particle size, blend uniformity, and capsule-shell properties.

Can an excipient supplier obtain patent protection around a COMETRIQ formulation?

Potentially, if it develops a genuinely novel and non-obvious composition, process, delivery system, or stability solution. Standard substitution of one conventional excipient for another is unlikely to create strong blocking protection.

References

1. Exelixis, Inc. (2024). COMETRIQ (cabozantinib) capsules, prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2012). FDA approves Cometriq to treat medullary thyroid cancer. FDA.

3. U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.

5. Exelixis, Inc. (2024). CABOMETYX (cabozantinib) tablets, prescribing information. U.S. Food and Drug Administration.